tavaborole profile

tavaborole: has antifungal activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

tavaborole : A member of the class of benzoxaboroles that is 1,3-dihydro-1-hydroxy-2,1-benzoxaborole substituted at position 5 by a fluoro group. A topical antifungal agent used for the treatment of onychomycosis (fungal infection of the toenails and fingernails). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	11499245
CHEMBL ID	443052
CHEBI ID	77942
SCHEMBL ID	500016
MeSH ID	M0501305

Synonym
tavaborole
an-2690 ,
sch-900340
2,1-benzoxaborole, 5-fluoro-1,3-dihydro-1-hydroxy-
5-fluoro-1-hydroxy-3h-2,1-benzoxaborole
CHEMBL443052
an2690
chebi:77942 ,
tavaborole (usan)
D10169
kerydin (tn)
AKOS006303927
bdbm50370987
HY-10980
CS-1058
k124a4euq3 ,
hsdb 8342
174671-46-6
5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole
kerydin
an 2690
tavaborole [usan:inn]
unii-k124a4euq3
NCGC00264110-01
5-fluoro-2,1-benzoxaborol-1(3h)-ol
tavaborole [who-dd]
tavaborole [usan]
tavaborole [vandf]
tavaborole [orange book]
tavaborole [inn]
tavaborole [mi]
S4996
5-fluoro-1,3-dihydro-2,1-benzoxaborol-1-ol
MB08883
5-fluorobenzo[c][1,2]oxaborol-1(3h)-ol
LFQDNHWZDQTITF-UHFFFAOYSA-N
1,3-dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole
5-fluoro-3h-benzo[c][1,2)oxaborol-1-ol
5-fluoro-3h-benzo[c][1,2]oxaborol-1-ol
SCHEMBL500016
T3775
AC-30887
FT-0697827
DTXSID00169888 ,
DB09041
mfcd10699483
EX-A1086
an-2690(tavaborole)
p-fluorbenzoxaborole
DS-8392
SY038332
5-fluoro-1-hydroxy-2,1-benzoxaborolane
Z1198279578
Q21011226
BCP08730
EN300-125084
5-fluoro-1-hydroxyl-1,3-dihydrobenzo[c][1,2]oxaborole
CCG-266215
NCGC00264110-02
tavaborole (an-2690)
F11396
d01ae24
tavaborol
tavaborolum
dtxcid5092379
tavaborole topical solution, 5%

Research Excerpts

Overview

Tavaborole is a broad-spectrum oxaborole antifungal agent with low molecular weight. It is approved by the US Food and Drug Administration for the treatment of toenail onychomycosis.

Excerpt	Reference	Relevance
"Tavaborole is a topical treatment option for onychomycosis."	( Planimetric Post-hoc Analysis of Women With Onychomycosis from Tavaborole 5% Phase III Studies: Evidence of Greater Improvements in Patients With >50% Baseline Infection. Gellings Lowe, N; Lipner, SR; Pariser, DM; Rycerz, AM; Wendelken, ME; Yost, JM, 2018)	1.44
"Tavaborole is a novel small-molecule antifungal agent recently approved in the United States for the topical treatment of toenail onychomycosis."	( Examining the Benefits of the Boron-Based Mechanism of Action and Physicochemical Properties of Tavaborole in the Treatment of Onychomycosis. Ghannoum, M; Gupta, AK; Markinson, B; Rock, F; Rycerz, A; Winter, T, 2018)	1.42
"Tavaborole is a broad-spectrum oxaborole antifungal agent with low molecular weight, permitting optimal nail plate penetration."	( Tavaborole for the treatment of onychomycosis. Elewski, BE; Tosti, A, 2014)	2.57
"Tavaborole is a novel, topical antifungal pharmaceutical agent pending FDA approval for the treatment of toenail onychomycosis due to dermatophytes. "	( Tavaborole for the treatment of onychomycosis. Elewski, BE; Tosti, A, 2014)	3.29
"Tavaborole is a novel, low-molecular weight oxaborole antifungal drug under development by Anacor Pharmaceuticals Inc. "	( Tavaborole: first global approval. Markham, A, 2014)	3.29
"Tavaborole is a novel, boron-based anti-fungal agent with greater nail plate penetration than its predecessors, due to its smaller molecular weight."	( Spotlight on tavaborole for the treatment of onychomycosis. Finch, J; Jinna, S, 2015)	1.51
"Tavaborole is a topical antifungal agent approved by the US Food and Drug Administration for the treatment of toenail onychomycosis. "	( Tavaborole, a Novel Boron-Containing Small Molecule Pharmaceutical Agent for Topical Treatment of Onychomycosis: I. Reproductive and Developmental Toxicity Studies. Chanda, S; Ciaravino, V; Coronado, D; Hoberman, A; Lanphear, C, 2016)	3.32
"Tavaborole is a topical antifungal agent approved by the US Food and Drug Administration for the treatment of toenail onychomycosis. "	( Tavaborole, a Novel Boron-Containing Small Molecule Pharmaceutical Agent for Topical Treatment of Onychomycosis: II. Prenatal and Postnatal Developmental Toxicity and Maternal Function Study. Chanda, S; Ciaravino, V; Coronado, D; Hoberman, A; Lanphear, C, 2016)	3.32
"Tavaborole is a new drug that addresses the unmet needs of currently available treatments."	( Tavaborole - a treatment for onychomycosis of the toenails. Gupta, AK; Versteeg, SG, 2016)	2.6

Effects

Excerpt	Reference	Relevance
"Tavaborole has a unique mechanism of action against fungal organisms and retains antifungal properties in the presence of keratin."	( Tavaborole (AN-2690) for the treatment of onychomycosis of the toenail in adults. Daigle, D; Gupta, AK, 2014)	2.57

Treatment

Tavaborole is a topical treatment option for onychomycosis. Tavaborole-treated polished nails showed no polish discoloration.

Excerpt	Reference	Relevance
"Tavaborole is a topical treatment option for onychomycosis."	( Planimetric Post-hoc Analysis of Women With Onychomycosis from Tavaborole 5% Phase III Studies: Evidence of Greater Improvements in Patients With >50% Baseline Infection. Gellings Lowe, N; Lipner, SR; Pariser, DM; Rycerz, AM; Wendelken, ME; Yost, JM, 2018)	1.44
"Tavaborole-treated polished nails showed no polish discoloration, and tavaborole applicators did not change in appearance during treatment. "	( Evaluation of the Appearance of Nail Polish Following Daily Treatment of Ex Vivo Human Fingernails With Topical Solutions of Tavaborole or Efinaconazole. Chanda, S; Coronado, D; Merchant, T; Vlahovic, TC; Zane, LT, 2016)	2.08

Toxicity

Excerpt	Reference	Relevance
" In rabbit embryo-fetal development toxicity studies dosed via oral or dermal administration, the no observable adverse effect level for maternal toxicity and embryo-fetal toxicity was 50 mg/kg/d (16 times the MRHD) and 5% (26 times the MRHD), respectively."	( Tavaborole, a Novel Boron-Containing Small Molecule Pharmaceutical Agent for Topical Treatment of Onychomycosis: I. Reproductive and Developmental Toxicity Studies. Chanda, S; Ciaravino, V; Coronado, D; Hoberman, A; Lanphear, C, 2016)	1.88
" The no observed adverse effect level (NOAEL) for maternal toxicity (F0 generation) was 60 mg/kg/d, based on the decreased activity observed in the 100 mg/kg/d dose group."	( Tavaborole, a Novel Boron-Containing Small Molecule Pharmaceutical Agent for Topical Treatment of Onychomycosis: II. Prenatal and Postnatal Developmental Toxicity and Maternal Function Study. Chanda, S; Ciaravino, V; Coronado, D; Hoberman, A; Lanphear, C, 2016)	1.88
" There are limited data on adverse events associated with the newer topical onychomycosis drugs."	( Retrospective analysis of adverse events with topical onychomycosis medications reported to the United States Food and Drug Administration. Lipner, SR; Wang, Y, 2020)	0.56

Dosage Studied

One double-blind, randomized, vehicle-controlled study (study 1) and two open-label studies (studies 2 and 3) examined the efficacy, safety, and optimal dosing concentration of tavaborole topical solution applied once daily or three times weekly for 180 days.

Excerpt	Relevance	Reference
"To assess the potential efficacy, safety, and optimal dosing concentration of tavaborole, a novel, boron-based pharmaceutical agent with broad-spectrum antifungal activity, for the treatment of onychomycosis of the toenail due to dermatophytes."	( The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis. Bucko, A; Herz-Ruelas, ME; Jarratt, MT; Jones, TM; Ocampo-Candiani, J; Pollak, RA; Toledo-Bahena, ME; Zane, LT, 2014)	0.93
"5%, were generally mild to moderate, and resolved with treatment discontinuation and/or a reduction in dosing frequency."	( The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis. Bucko, A; Herz-Ruelas, ME; Jarratt, MT; Jones, TM; Ocampo-Candiani, J; Pollak, RA; Toledo-Bahena, ME; Zane, LT, 2014)	0.7
"In study 1, tavaborole penetration was evaluated over 20 days of dosing using the Franz finite dose technique and modified Franz diffusion cells."	( In Vitro Nail Penetration of Tavaborole Topical Solution, 5%, Through Nail Polish on Ex Vivo Human Fingernails. Chanda, S; Coronado, D; MPharm, TM; Vlahovic, T; Zane, LT, 2015)	1.09
" Nail polish appearance after application of tavaborole (dropper) or efinaconazole (brush); respective applicator appearance; presence of color transfer from respective applicators; and color transfer to remaining solutions after dosing of polished nails were evaluated."	( Evaluation of the Appearance of Nail Polish Following Daily Treatment of Ex Vivo Human Fingernails With Topical Solutions of Tavaborole or Efinaconazole. Chanda, S; Coronado, D; Merchant, T; Vlahovic, TC; Zane, LT, 2016)	0.9
" Dropper and brush applicators were applied to white watercolor paper immediately after dosing to evaluate color transfer from polished nails."	( Evaluation of the Appearance of Nail Polish Following Daily Treatment of Ex Vivo Human Fingernails With Topical Solutions of Tavaborole or Efinaconazole. Chanda, S; Coronado, D; Merchant, T; Vlahovic, TC; Zane, LT, 2016)	0.64
" In rabbit embryo-fetal development toxicity studies dosed via oral or dermal administration, the no observable adverse effect level for maternal toxicity and embryo-fetal toxicity was 50 mg/kg/d (16 times the MRHD) and 5% (26 times the MRHD), respectively."	( Tavaborole, a Novel Boron-Containing Small Molecule Pharmaceutical Agent for Topical Treatment of Onychomycosis: I. Reproductive and Developmental Toxicity Studies. Chanda, S; Ciaravino, V; Coronado, D; Hoberman, A; Lanphear, C, 2016)	1.88

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Role	Description
antifungal agent	An antimicrobial agent that destroys fungi by suppressing their ability to grow or reproduce.
protein synthesis inhibitor	A compound, usually an anti-bacterial agent or a toxin, which inhibits the synthesis of a protein.
EC 6.1.1.4 (leucine--tRNA ligase) inhibitor	An EC 6.1.1.* (ligases forming aminoacyl tRNA and related compounds) inhibitor that inhibits the action of leucine--tRNA synthetase (EC 6.1.1.4).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
organofluorine compound	An organofluorine compound is a compound containing at least one carbon-fluorine bond.
benzoxaborole	Any organic heterobicyclic compound that consists of an oxoborole ring that is ortho-fused to a benzene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Carbonic anhydrase 1	Homo sapiens (human)	Ki	2.0150	0.0000	1.3726	10.0000	AID1504709
Carbonic anhydrase 2	Homo sapiens (human)	Ki	0.4620	0.0000	0.7236	9.9200	AID1504710; AID1726062
Leucine--tRNA ligase, cytoplasmic	Saccharomyces cerevisiae S288C	IC50 (µMol)	2.1000	2.1000	2.1000	2.1000	AID289193
Leucine--tRNA ligase, cytoplasmic	Saccharomyces cerevisiae S288C	Ki	16.6250	1.8500	1.8500	1.8500	AID289191; AID289192
Carbonic anhydrase	Cryptococcus neoformans var. grubii	Ki	0.0890	0.0100	0.7364	8.3470	AID1504707
Carbonic anhydrase	Nakaseomyces glabratus CBS 138	Ki	0.0720	0.0070	1.2174	9.1700	AID1504708
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
one-carbon metabolic process	Carbonic anhydrase 1	Homo sapiens (human)
morphogenesis of an epithelium	Carbonic anhydrase 2	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Carbonic anhydrase 2	Homo sapiens (human)
positive regulation of cellular pH reduction	Carbonic anhydrase 2	Homo sapiens (human)
angiotensin-activated signaling pathway	Carbonic anhydrase 2	Homo sapiens (human)
regulation of monoatomic anion transport	Carbonic anhydrase 2	Homo sapiens (human)
secretion	Carbonic anhydrase 2	Homo sapiens (human)
regulation of intracellular pH	Carbonic anhydrase 2	Homo sapiens (human)
neuron cellular homeostasis	Carbonic anhydrase 2	Homo sapiens (human)
positive regulation of dipeptide transmembrane transport	Carbonic anhydrase 2	Homo sapiens (human)
regulation of chloride transport	Carbonic anhydrase 2	Homo sapiens (human)
carbon dioxide transport	Carbonic anhydrase 2	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
arylesterase activity	Carbonic anhydrase 1	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 1	Homo sapiens (human)
protein binding	Carbonic anhydrase 1	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 1	Homo sapiens (human)
hydro-lyase activity	Carbonic anhydrase 1	Homo sapiens (human)
cyanamide hydratase activity	Carbonic anhydrase 1	Homo sapiens (human)
arylesterase activity	Carbonic anhydrase 2	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 2	Homo sapiens (human)
protein binding	Carbonic anhydrase 2	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 2	Homo sapiens (human)
cyanamide hydratase activity	Carbonic anhydrase 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytosol	Carbonic anhydrase 1	Homo sapiens (human)
extracellular exosome	Carbonic anhydrase 1	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 2	Homo sapiens (human)
cytosol	Carbonic anhydrase 2	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 2	Homo sapiens (human)
myelin sheath	Carbonic anhydrase 2	Homo sapiens (human)
apical part of cell	Carbonic anhydrase 2	Homo sapiens (human)
extracellular exosome	Carbonic anhydrase 2	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 2	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 2	Homo sapiens (human)
apical part of cell	Carbonic anhydrase 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (65)

Assay ID	Title	Year	Journal	Article
AID289206	Antifungal activity against Cladosporium cladosporioides ATCC 16022	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID1504708	Inhibition of Candida glabrata Nce103 incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay	2017	ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11	Benzoxaboroles as Efficient Inhibitors of the β-Carbonic Anhydrases from Pathogenic Fungi: Activity and Modeling Study.
AID289208	Antifungal activity against Trichophyton rubrum ATCC 18759	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID289207	Antifungal activity against Fusarium solani ATCC 36031	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID1297994	Inhibition of Trypanosoma brucei LeuRS assessed as formation of stable tRNA(Leu)-compound adduct in editing site of enzyme	2016	Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11	Repurposing strategies for tropical disease drug discovery.
AID1569289	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	2019	Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14	Design, Synthesis, and Structure-Activity Relationship of 7-Propanamide Benzoxaboroles as Potent Anticancer Agents.
AID289192	Inhibition of Saccharomyces cerevisiae cytoplasmic leucyl-tRNA synthetase after 20 mins	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID1504707	Inhibition of Cryptococcus neoformans Can2 incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay	2017	ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11	Benzoxaboroles as Efficient Inhibitors of the β-Carbonic Anhydrases from Pathogenic Fungi: Activity and Modeling Study.
AID289210	Antifungal activity against Epidermophyton floccosum ATCC 525066	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID1850491	Antifungal activity against Aspergillus niger assessed as fungal growth inhibition incubated for 48 hrs by agar diffusion method	2022	Bioorganic & medicinal chemistry, 06-01, Volume: 63	Boron-Containing heterocycles as promising pharmacological agents.
AID289216	Antimicrobial activity against AN2690-resistant Saccharomyces cerevisiae ANA323 with CDC60 G405V mutation	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID289214	Antimicrobial activity against AN2690-resistant Saccharomyces cerevisiae ANA321 with CDC60 R316I mutation	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID289196	Antifungal activity against Candida glabrata ATCC 90030	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID1504709	Inhibition of human carbonic anhydrase-1 incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay	2017	ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11	Benzoxaboroles as Efficient Inhibitors of the β-Carbonic Anhydrases from Pathogenic Fungi: Activity and Modeling Study.
AID266927	Antifungal activity against Candida albicans	2006	Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15	Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis.
AID289209	Antifungal activity against Trichophyton mentagrophytes ATCC 28185	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID1726065	Selectivity index, ratio of Ki for human carbonic anhydrase 2 to Ki for Vibrio cholerae gamma carbonic anhydrase
AID289213	Antimicrobial activity against AN2690-resistant Saccharomyces cerevisiae ANA320 with CDC60 N415D mutation	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID289193	Inhibition of Saccharomyces cerevisiae cytoplasmic leucyl-tRNA synthetase assessed as tRNA amino-acylation	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID289202	Antifungal activity against Aspergillus fumigatus ATCC 13073	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID289198	Antifungal activity against Candida tropicalis ATCC 13803	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID1569288	Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay	2019	Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14	Design, Synthesis, and Structure-Activity Relationship of 7-Propanamide Benzoxaboroles as Potent Anticancer Agents.
AID1863505	Inhibition of full length DENV2 NS2B-NS3 protease in human HeLa cells expressing luciferase reporter gene at 12.5 uM incubated for 24 hrs by luminescence analysis relative to control
AID289199	Antifungal activity against Cryptococcus neoformans F285	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID1864430	Inhibition of NLRP3 inflammasome activation in LPS-primed mouse J774.A1 cells assessed as reduction in IL-1beta secretion at 1 uM	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of a Novel Oral Proteasome Inhibitor to Block NLRP3 Inflammasome Activation with Anti-inflammation Activity.
AID289190	Inhibition of protein synthesis in Saccharomyces cerevisiae S288C after 15 mins	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID289215	Antimicrobial activity against AN2690-resistant Saccharomyces cerevisiae ANA322 with CDC60 C326F mutation	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID289212	Antifungal activity against Microsporum gypseum ATCC 24103	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID289211	Antifungal activity against Microsporum audouinii ATCC 42558	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID1726062	Inhibition of human carbonic anhydrase 2 incubated for 30 mins prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay
AID266926	Antifungal activity against Trichophyton mentagrophytes	2006	Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15	Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis.
AID289189	Inhibition of Saccharomyces cerevisiae cytoplasmic leucyl-tRNA synthetase assessed as [3H]IleutRNA-Leu hydrolysis by post-transfer editing assay	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID289195	Antifungal activity against Candida albicans ATCC 90028	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID1726064	Selectivity index, ratio of Ki for human carbonic anhydrase 2 to Ki for Vibrio cholerae beta carbonic anhydrase
AID1863504	Inhibition of full length DENV2 NS2B-NS3 protease in human HeLa cells expressing luciferase reporter gene incubated for 24 hrs by luminescence analysis
AID289204	Antifungal activity against Alternaria alternata ATCC 6663	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID1726063	Selectivity index, ratio of Ki for human carbonic anhydrase 2 to Ki for Vibrio cholerae alpha carbonic anhydrase
AID1504706	Inhibition of Malassezia globosa beta-carbonic anhydrase incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay	2017	ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11	Benzoxaboroles as Efficient Inhibitors of the β-Carbonic Anhydrases from Pathogenic Fungi: Activity and Modeling Study.
AID1726059	Inhibition of Vibrio cholerae alpha carbonic anhydrase incubated for 30 mins prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay
AID289219	Antimicrobial activity against AN2690-resistant Saccharomyces cerevisiae ANA327 with CDC60 T314M mutation	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID289221	Antimicrobial activity against AN2690-resistant Saccharomyces cerevisiae ANA360 with CDC60 T319I mutation	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID289194	Antimicrobial activity against Saccharomyces cerevisiae ATCC 201388	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID1504710	Inhibition of human carbonic anhydrase-2 incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay	2017	ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11	Benzoxaboroles as Efficient Inhibitors of the β-Carbonic Anhydrases from Pathogenic Fungi: Activity and Modeling Study.
AID266925	Antifungal activity against Trichophyton rubrum	2006	Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15	Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis.
AID266928	Antifungal activity against Cryptococcus neoformans	2006	Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15	Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis.
AID289222	Antimicrobial activity against Saccharomyces cerevisiae in synthetic defined media without leucine	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID1569291	Cytotoxicity against human WI38 cells after 72 hrs by MTT assay	2019	Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14	Design, Synthesis, and Structure-Activity Relationship of 7-Propanamide Benzoxaboroles as Potent Anticancer Agents.
AID289191	Inhibition of Saccharomyces cerevisiae cytoplasmic leucyl-tRNA synthetase after 2 mins	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID289218	Antimicrobial activity against AN2690-resistant Saccharomyces cerevisiae ANA326 with CDC60 L315V mutation	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID289220	Antimicrobial activity against AN2690-resistant Saccharomyces cerevisiae ANA358 with CDC60 S416L mutation	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID289197	Antifungal activity against Candida krusei ATCC 44507	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID289223	Binding affinity to Saccharomyces cerevisiae cytoplasmic leucyl-tRNA synthetase in presence of AMP	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID289205	Antifungal activity against Penicillium chrysogenum ATCC 10108	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID1863503	Inhibition of C-terminal His tagged SARS CoV-2 main protease transfected in Escherichia coli BL21 (DE3) using 2-Abz-Ser-AlaVal-Leu-Gln-Ser-Gly-Tyr(3-NO2)-Arg-OH as substrate at 50 uM preincubated for 15 mins followed by substrate addition and measured aft
AID289201	Antifungal activity against Malassezia pachydermatis ATCC 96746	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID1726061	Inhibition of Vibrio cholerae gamma carbonic anhydrase incubated for 30 mins prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay
AID1569290	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	2019	Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14	Design, Synthesis, and Structure-Activity Relationship of 7-Propanamide Benzoxaboroles as Potent Anticancer Agents.
AID289200	Antifungal activity against Malassezia furfur ATCC 44344	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID289203	Antifungal activity against Rhizopus microsporus ATCC 66276	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID266929	Antifungal activity against Aspergillus fumigatus	2006	Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15	Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis.
AID1863502	Inhibition of C-terminal His tagged SARS CoV-2 main protease transfected in Escherichia coli BL21 (DE3) using 2-Abz-Ser-AlaVal-Leu-Gln-Ser-Gly-Tyr(3-NO2)-Arg-OH as substrate preincubated for 15 mins followed by substrate addition and measured after 15 min
AID1863506	Cytotoxicity against human HeLa cells expressing luciferase-based DENV-2 protease reporter system assessed as reduction in cell viability by celltiter-blue assay
AID1726060	Inhibition of Vibrio cholerae beta carbonic anhydrase incubated for 30 mins prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay
AID1380105	Inhibition of Saccharomyces cerevisiae LeuRs	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Emerging New Targets for the Treatment of Resistant Fungal Infections.
AID289217	Antimicrobial activity against AN2690-resistant Saccharomyces cerevisiae ANA324 with CDC60 C326R mutation	2007	Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (8.33)	29.6817
2010's	56 (77.78)	24.3611
2020's	10 (13.89)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	9 (12.00%)	5.53%
Reviews	21 (28.00%)	6.00%
Case Studies	1 (1.33%)	4.05%
Observational	0 (0.00%)	0.25%
Other	44 (58.67%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (11)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
An Open-label Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Kerydin (Registered) (Tavaborole) Topical Solution, 5% In The Treatment Of Onychomycosis Of The Toenail In Pediatric Subjects Ages 6 To 16 Years And 11 Months [NCT03405818]	Phase 4	55 participants (Actual)	Interventional	2015-10-22	Completed
A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN2690 2.5%, 5.0%, and 7.5% Solutions vs. Vehicle for the Treatment of Adult Subjects With Onychomycosis of the Great Toenail [NCT00679965]	Phase 2	159 participants (Actual)	Interventional	2006-02-28	Completed
A Randomized, Double-blind, Vehicle-controlled, Multi-center Study To Evaluate The Safety And Efficacy Of Topically Applied An2690 2.5%, 5.0%, And 7.5% Solutions Vs. Vehicle For The Treatment Of Adult Subjects With Onychomycosis Of The Great Toenail. [NCT00679770]	Phase 2	28 participants (Actual)	Interventional	2006-06-30	Completed
An Open-label, Multiple-dose Study Of The Absorption And Systemic Pharmacokinetics Of An2690 Applied As A 7.5% Solution To All Toenails Of Adult Patients With Moderate To Severe Onychomycosis [NCT00680160]	Phase 2	15 participants (Actual)	Interventional	2006-04-30	Completed
An Open-Label, Rising Multiple-Dose, Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN2690 5.0% and 7.5% Solution for the Treatment of Adult Subjects With Onychomycosis of the Great Toenail [NCT00679523]	Phase 2	60 participants (Actual)	Interventional	2005-11-30	Completed
An Open-label, Multiple-dose Study Of The Absorption And Systemic Pharmacokinetics Of An2690 Applied As A 7.5% Solution To All Toenails Of Adult Patients With Moderate To Severe Onychomycosis [NCT00679601]	Phase 2	20 participants (Actual)	Interventional	2007-03-31	Completed
21-day Cumulative Irritation Test [NCT00680095]	Phase 1	37 participants (Actual)	Interventional	2007-01-22	Completed
An Open Label, Multi-center Study To Evaluate The Safety And Efficacy Of Topically Applied An2690 1% And 5% Solutions For The Treatment Of Adult Subjects With Onychomycosis Of The Great Toenail [NCT00680134]	Phase 2	60 participants (Actual)	Interventional	2006-06-30	Completed
A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults [NCT01302119]	Phase 3	604 participants (Actual)	Interventional	2011-02-28	Completed
An Open-Label, Rising Multiple-Dose, Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN2690 5.0% and 7.5% Solution for the Treatment of Adult Subjects With Onychomycosis of the Great Toenail [NCT01278394]	Phase 2	29 participants (Actual)	Interventional	2007-03-31	Completed
A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults [NCT01270971]	Phase 3	594 participants (Actual)	Interventional	2010-12-01	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT01270971 (4) [back to overview]	Treatment Success (Completely Clear or Almost Clear Nail and Negative Mycology) of Target Great Toenail at Week 52
NCT01270971 (4) [back to overview]	Complete Cure (Completely Clear Nail and Negative Mycology) of Target Great Toenail at Week 52
NCT01270971 (4) [back to overview]	Completely Clear or Almost Clear Target Great Toenail at Week 52
NCT01270971 (4) [back to overview]	Negative Mycology of Target Great Toenail at Week 52
NCT01278394 (7) [back to overview]	Mycological Evaluations (Negative KOH and Negative Fungal Culture) Compared to Baseline
NCT01278394 (7) [back to overview]	Clear Nail Growth of the Targeted Toenail
NCT01278394 (7) [back to overview]	Length of Time to Clinical Evaluation of Clear or at Least 5 mm of CNG
NCT01278394 (7) [back to overview]	Clinical Evidence of Complete Clearance of the Treatment-targeted Great Toenail Plus a Negative Fungal Culture at Day 360
NCT01278394 (7) [back to overview]	Mycological Evaluations (Negative KOH and Negative Fungal Culture) Compared to Baseline
NCT01278394 (7) [back to overview]	Mycological Evaluations (Negative KOH and Negative Fungal Culture) Compared to Baseline
NCT01278394 (7) [back to overview]	Mycological Evaluations (Negative Potassium Hydroxide (KOH) and Negative Fungal Culture) Compared to Baseline
NCT01302119 (4) [back to overview]	Complete Cure (Completely Clear Nail and Negative Mycology) of Target Great Toenail at Week 52
NCT01302119 (4) [back to overview]	Completely Clear or Almost Clear Target Great Toenail at Week 52
NCT01302119 (4) [back to overview]	Treatment Success (Completely Clear or Almost Clear Nail and Negative Mycology) of Target Great Toenail at Week 52
NCT01302119 (4) [back to overview]	Negative Mycology of Target Great Toenail at Week 52
NCT03405818 (38) [back to overview]	Change From Baseline in Chemistry Parameters (Albumin and Protein) at Week 52
NCT03405818 (38) [back to overview]	Change From Baseline in Chemistry Parameters (Bilirubin, Creatinine, Glucose [Non-fasting] and Urea Nitrogen) at Week 24
NCT03405818 (38) [back to overview]	Change From Baseline in Chemistry Parameters (Bilirubin, Creatinine, Glucose [Non-fasting] and Urea Nitrogen) at Week 52
NCT03405818 (38) [back to overview]	Change From Baseline in Chemistry Parameters (Potassium and Sodium) at Week 24
NCT03405818 (38) [back to overview]	Change From Baseline in Chemistry Parameters (Potassium and Sodium) at Week 52
NCT03405818 (38) [back to overview]	Change From Baseline in Hematology Parameter (Erythrocytes) at Week 24
NCT03405818 (38) [back to overview]	Change From Baseline in Hematology Parameter (Hematocrit) at Week 24
NCT03405818 (38) [back to overview]	Change From Baseline in Hematology Parameters (Hemoglobin) at Week 24
NCT03405818 (38) [back to overview]	Change From Baseline in Hematology Parameters (Leukocytes and Platelets) at Week 24
NCT03405818 (38) [back to overview]	Change From Baseline in Hematology Parameters (Leukocytes and Platelets) at Week 52
NCT03405818 (38) [back to overview]	Change From Baseline in Hematology Parameters (Leukocytes: Basophils, Eosinophils, Lymphocytes, Monocytes and Neutrophils) at Week 24
NCT03405818 (38) [back to overview]	Change From Baseline in Vital Sign (Respiratory Rate) at Week 52
NCT03405818 (38) [back to overview]	Change From Baseline in Vital Sign (Blood Pressure) at Week 24
NCT03405818 (38) [back to overview]	Change From Baseline in Vital Sign (Blood Pressure) at Week 52
NCT03405818 (38) [back to overview]	Change From Baseline in Vital Sign (Pulse Rate) at Week 24
NCT03405818 (38) [back to overview]	Change From Baseline in Vital Sign (Respiratory Rate) at Week 24
NCT03405818 (38) [back to overview]	Number of Participants With Adverse Events (AEs) By Severity
NCT03405818 (38) [back to overview]	Number of Participants With Local Tolerability Reactions by Severity
NCT03405818 (38) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
NCT03405818 (38) [back to overview]	Percentage of Participants With Almost Complete Cure of Target Great Toenail (TGT) at Week 24 and 52
NCT03405818 (38) [back to overview]	Percentage of Participants With Clinical Efficacy of Target Great Toenail (TGT) at Week 24 and 52
NCT03405818 (38) [back to overview]	Percentage of Participants With Mycological Cure of Target Great Toenail (TGT) at Week 24 and 52
NCT03405818 (38) [back to overview]	Percentage of Participants With Negative Fungal Culture of the Target Great Toenail (TGT) at Weeks 24 and 52
NCT03405818 (38) [back to overview]	Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity (AUCinf) of Tavaborole
NCT03405818 (38) [back to overview]	Area Under the Plasma Concentration-Time Curve From Hour Zero to Hour 24 (AUC24) of Tavaborole
NCT03405818 (38) [back to overview]	Change From Baseline in Hematology Parameter (Erythrocytes) at Week 52
NCT03405818 (38) [back to overview]	Change From Baseline in Hematology Parameter (Hematocrit) at Week 52
NCT03405818 (38) [back to overview]	Change From Baseline in Hematology Parameters (Hemoglobin) at Week 52
NCT03405818 (38) [back to overview]	Change From Baseline in Vital Sign (Pulse Rate) at Week 52
NCT03405818 (38) [back to overview]	Elimination Half-Life of Tavaborole
NCT03405818 (38) [back to overview]	Elimination Rate Constant of Tavaborole
NCT03405818 (38) [back to overview]	Change From Baseline in Hematology Parameters (Leukocytes: Basophils, Eosinophils, Lymphocytes, Monocytes and Neutrophils) at Week 52
NCT03405818 (38) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Tavaborole
NCT03405818 (38) [back to overview]	Percentage of Participants With Complete Cure of Target Great Toenail (TGT) at Week 52
NCT03405818 (38) [back to overview]	Time to Maximum Observed Plasma Concentration (Tmax) of Tavaborole
NCT03405818 (38) [back to overview]	Change From Baseline in Chemistry Parameters (Alanine Aminotransferase, Alkaline Phosphatase and Aspartate Aminotransferase) at Week 24
NCT03405818 (38) [back to overview]	Change From Baseline in Chemistry Parameters (Alanine Aminotransferase, Alkaline Phosphatase and Aspartate Aminotransferase) at Week 52
NCT03405818 (38) [back to overview]	Change From Baseline in Chemistry Parameters (Albumin and Protein) at Week 24

Treatment Success (Completely Clear or Almost Clear Nail and Negative Mycology) of Target Great Toenail at Week 52

No clinical evidence of onychomycosis as evidenced by normal toenail plate, no onycholysis, and no subungual hyperkeratosis, or no more than minimal evidence of onychomycosis as evidenced by toenail plate dystrophic or discolored over ≤ 10% of the distal aspect, with minimally evident onycholysis and subungual hyperkeratosis, and negative KOH wet mount and negative fungal culture. (NCT01270971)
Timeframe: Week 52

Intervention	participants (Number)
	Success	Failure
AN2690 Topical Solution, 5%	61	338
Solution Vehicle	3	191

Intervention	participants (Number)
	Fungal Culture Result Positive	Fungal Culture Result Negative	KOH Result Positive	KOH Result Negative
AN2690 Solution, 5.0%	1	28	17	12

Intervention	gram per deciliter (g/dL) (Mean)
	Change at Week 52: Albumin	Change at Week 52: Protein
Kerydin	-0.08	-0.07

Intervention	milligram per deciliter (mg/dL) (Mean)
	Baseline: Bilirubin	Baseline: Creatinine	Baseline: Glucose [non-fasting]	Baseline: Urea Nitrogen	Change at Week 24: Bilirubin	Change at Week 24: Creatinine	Change at Week 24: Glucose [non-fasting]	Change at Week 24: Urea Nitrogen
Kerydin	0.46	0.68	87.5	13.5	0.03	0.01	0.0	-0.1

Intervention	milligram per deciliter (mg/dL) (Mean)
	Change at Week 52: Bilirubin	Change at Week 52: Creatinine	Change at Week 52: Glucose [non-fasting]	Change at Week 52: Urea Nitrogen
Kerydin	-0.01	0.04	5.9	-0.7

Intervention	millimole per liter (mmol/L) (Mean)
	Baseline: Potassium	Baseline: Sodium	Change at Week 24: Potassium	Change at Week 24: Sodium
Kerydin	4.25	138.0	-0.05	1.6

Intervention	millimole per liter (mmol/L) (Mean)
	Change at Week 52: Potassium	Change at Week 52: Sodium
Kerydin	0.00	2.1

Intervention	10^9 cells per liter (Mean)
	Baseline: Leukocytes	Baseline: Platelets	Change at Week 24: Leukocytes	Change at Week 24: Platelets
Kerydin	7.11	255.6	-0.51	-4.1

Intervention	10^9 cells per liter (Mean)
	Change at Week 52: Leukocytes	Change at Week 52: Platelets
Kerydin	-0.62	-9.4

Intervention	percentage of leukocytes (Mean)
	Baseline: Basophils/Leukocytes	Baseline: Eosinophil/Leukocytes	Baseline: Lymphocytes/Leukocytes	Baseline: Monocytes/Leukocytes	Baseline: Neutrophils/Leukocytes	Change at Week 24: Basophils/Leukocytes	Change at Week 24: Eosinophil/Leukocytes	Change at Week 24: Lymphocytes/Leukocytes	Change at Week 24: Monocytes/Leukocytes	Change at Week 24: Neutrophils/Leukocytes
Kerydin	0.6	3.3	34.4	6.8	55.1	0.1	-0.5	1.1	-0.2	-0.7

Intervention	millimeter of mercury (mmHg) (Mean)
	Baseline: Systolic Blood Pressure	Baseline: Diastolic Blood Pressure	Change at Week 24: Systolic Blood Pressure	Change at Week 24: Diastolic Blood Pressure
Kerydin	110.9	68.3	0.4	1.0

Intervention	millimeter of mercury (mmHg) (Mean)
	Change at Week 52: Systolic Blood Pressure	Change at Week 52: Diastolic Blood Pressure
Kerydin	0.1	1.0

Intervention	Participants (Count of Participants)
	None Burning/Stinging	Mild Burning/Stinging	Moderate Burning/Stinging	Severe Burning/Stinging	None Induration/Edema	Mild Induration/Edema	Moderate Induration/Edema	Severe Induration/Edema	None Oozing and Crusting	Mild Oozing and Crusting	Moderate Oozing and Crusting	Severe Oozing and Crusting	None Pruritus	Mild Pruritus	Moderate Pruritus	Severe Pruritus	None Erythema	Mild Erythema	Moderate Erythema	Severe Erythema	None Scaling	Mild Scaling	Moderate Scaling	Severe Scaling
Kerydin	54	0	1	0	53	4	2	1	54	2	1	0	53	2	1	0	50	6	2	0	51	4	3	1

Intervention	percentage of leukocytes (Mean)
	Change at Week 52: Basophils/Leukocytes	Change at Week 52: Eosinophils/Leukocytes	Change at Week 52: Lymphocytes/Leukocytes	Change at Week 52: Monocytes/Leukocytes	Change at Week 52: Neutrophils/Leukocytes
Kerydin	0.1	0.3	0.7	-0.5	-0.7

Intervention	International Unit per liter (IU/L) (Mean)
	Baseline: Alanine Aminotransferase	Baseline: Alkaline Phosphatase	Baseline: Aspartate Aminotransferase	Change at Week 24:Alanine Aminotransferase	Change at Week 24:Alkaline Phosphatase	Change at Week 24:Aspartate Aminotransferase
Kerydin	14.6	178.7	21.7	-1.7	-1.5	-3.3

Intervention	International Unit per liter (IU/L) (Mean)
	Change at Week 52:Alanine Aminotransferase	Change at Week 52:Alkaline Phosphatase	Change at Week 52:Aspartate Aminotransferase
Kerydin	-1.6	-18.4	-2.7

Intervention	gram per deciliter (g/dL) (Mean)
	Baseline: Albumin	Baseline: Protein	Change at Week 24: Albumin	Change at Week 24: Protein
Kerydin	4.49	6.94	-0.05	-0.04

Condition	Indicated	Relationship Strength	Studies	Trials
Nail Fungus [description not available]	0	12.64	44	9
Onychomycosis A fungal infection of the nail, usually caused by DERMATOPHYTES; YEASTS; or nondermatophyte MOLDS.	1	14.64	44	9
Neglected Diseases Diseases that are underfunded and have low name recognition but are major burdens in less developed countries. The World Health Organization has designated six tropical infectious diseases as being neglected in industrialized countries that are endemic in many developing countries (HELMINTHIASIS; LEPROSY; LYMPHATIC FILARIASIS; ONCHOCERCIASIS; SCHISTOSOMIASIS; and TRACHOMA).	0	3.04	1	0
Fungal Diseases [description not available]	0	3.46	2	0
Mycoses Diseases caused by FUNGI.	0	3.46	2	0
Cancer of Ovary [description not available]	0	2.21	1	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	0	2.21	1	0
Cystic Fibrosis of Pancreas [description not available]	0	2.6	1	0
Infections, Pseudomonas [description not available]	0	2.6	1	0
Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.	0	2.6	1	0
Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS.	0	2.6	1	0
Erythema Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of disease processes.	0	3.94	2	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	0	2.59	2	0
Blood Pressure, High [description not available]	0	3.56	1	1
Foot Dermatoses Skin diseases of the foot, general or unspecified.	0	11.3	23	8
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	0	3.56	1	1
Eczema, Atopic [description not available]	0	3.46	2	0
Kahler Disease [description not available]	0	3.12	1	0
Dermatitis, Atopic A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.	0	3.46	2	0
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	0	3.12	1	0
Hand Dermatosis [description not available]	0	3.66	3	0
Hand Dermatoses Skin diseases involving the HANDS.	0	3.66	3	0
ADDH [description not available]	0	2.1	1	0
Allergy, Food [description not available]	0	2.1	1	0
Dermatoses [description not available]	0	2.1	1	0
Attention Deficit Disorder with Hyperactivity A behavior disorder originating in childhood in which the essential features are signs of developmentally inappropriate inattention, impulsivity, and hyperactivity. Although most individuals have symptoms of both inattention and hyperactivity-impulsivity, one or the other pattern may be predominant. The disorder is more frequent in males than females. Onset is in childhood. Symptoms often attenuate during late adolescence although a minority experience the full complement of symptoms into mid-adulthood. (From DSM-V)	0	2.1	1	0
Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.	0	2.1	1	0
Food Hypersensitivity Gastrointestinal disturbances, skin eruptions, or shock due to allergic reactions to allergens in food.	0	2.1	1	0
Skin Diseases Diseases involving the DERMIS or EPIDERMIS.	0	2.1	1	0
Athlete's Foot [description not available]	0	3.01	1	0
Tinea Pedis Dermatological pruritic lesion in the feet, caused by Trichophyton rubrum, T. mentagrophytes, or Epidermophyton floccosum.	0	3.01	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	2.53	2	0
Acute Liver Injury, Drug-Induced [description not available]	0	3.04	1	0
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	0	3.04	1	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	0	2.13	1	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	0	2.13	1	0
Dermatomycoses Superficial infections of the skin or its appendages by any of various fungi.	0	3.06	1	0

tavaborole

Description

Cross-References

Synonyms (66)

Research Excerpts

Overview

Effects

Treatment

Toxicity

Dosage Studied

Roles (3)

Drug Classes (2)

Protein Targets (5)

Inhibition Measurements

Activation Measurements

Biological Processes (12)

Molecular Functions (6)

Ceullar Components (6)

Bioassays (65)

Research

Studies (72)

Market Indicators

Research Demand Index: 53.67

Study Types

Clinical Trials (11)

Trial Overview

Trial Outcomes

Treatment Success (Completely Clear or Almost Clear Nail and Negative Mycology) of Target Great Toenail at Week 52

Complete Cure (Completely Clear Nail and Negative Mycology) of Target Great Toenail at Week 52

Completely Clear or Almost Clear Target Great Toenail at Week 52

Negative Mycology of Target Great Toenail at Week 52

Mycological Evaluations (Negative KOH and Negative Fungal Culture) Compared to Baseline

Clear Nail Growth of the Targeted Toenail

Length of Time to Clinical Evaluation of Clear or at Least 5 mm of CNG

Clinical Evidence of Complete Clearance of the Treatment-targeted Great Toenail Plus a Negative Fungal Culture at Day 360

Mycological Evaluations (Negative KOH and Negative Fungal Culture) Compared to Baseline

Mycological Evaluations (Negative KOH and Negative Fungal Culture) Compared to Baseline

Mycological Evaluations (Negative Potassium Hydroxide (KOH) and Negative Fungal Culture) Compared to Baseline

Complete Cure (Completely Clear Nail and Negative Mycology) of Target Great Toenail at Week 52

Completely Clear or Almost Clear Target Great Toenail at Week 52

Treatment Success (Completely Clear or Almost Clear Nail and Negative Mycology) of Target Great Toenail at Week 52

Negative Mycology of Target Great Toenail at Week 52

Change From Baseline in Chemistry Parameters (Albumin and Protein) at Week 52

Change From Baseline in Chemistry Parameters (Bilirubin, Creatinine, Glucose [Non-fasting] and Urea Nitrogen) at Week 24

Change From Baseline in Chemistry Parameters (Bilirubin, Creatinine, Glucose [Non-fasting] and Urea Nitrogen) at Week 52

Change From Baseline in Chemistry Parameters (Potassium and Sodium) at Week 24

Change From Baseline in Chemistry Parameters (Potassium and Sodium) at Week 52

Change From Baseline in Hematology Parameter (Erythrocytes) at Week 24

Change From Baseline in Hematology Parameter (Hematocrit) at Week 24

Change From Baseline in Hematology Parameters (Hemoglobin) at Week 24

Change From Baseline in Hematology Parameters (Leukocytes and Platelets) at Week 24

Change From Baseline in Hematology Parameters (Leukocytes and Platelets) at Week 52

Change From Baseline in Hematology Parameters (Leukocytes: Basophils, Eosinophils, Lymphocytes, Monocytes and Neutrophils) at Week 24

Change From Baseline in Vital Sign (Respiratory Rate) at Week 52

Change From Baseline in Vital Sign (Blood Pressure) at Week 24

Change From Baseline in Vital Sign (Blood Pressure) at Week 52

Change From Baseline in Vital Sign (Pulse Rate) at Week 24

Change From Baseline in Vital Sign (Respiratory Rate) at Week 24

Number of Participants With Adverse Events (AEs) By Severity

Number of Participants With Local Tolerability Reactions by Severity

Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

Percentage of Participants With Almost Complete Cure of Target Great Toenail (TGT) at Week 24 and 52

Percentage of Participants With Clinical Efficacy of Target Great Toenail (TGT) at Week 24 and 52

Percentage of Participants With Mycological Cure of Target Great Toenail (TGT) at Week 24 and 52

Percentage of Participants With Negative Fungal Culture of the Target Great Toenail (TGT) at Weeks 24 and 52

Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity (AUCinf) of Tavaborole

Area Under the Plasma Concentration-Time Curve From Hour Zero to Hour 24 (AUC24) of Tavaborole

Change From Baseline in Hematology Parameter (Erythrocytes) at Week 52

Change From Baseline in Hematology Parameter (Hematocrit) at Week 52

Change From Baseline in Hematology Parameters (Hemoglobin) at Week 52

Change From Baseline in Vital Sign (Pulse Rate) at Week 52

Elimination Half-Life of Tavaborole

Elimination Rate Constant of Tavaborole

Change From Baseline in Hematology Parameters (Leukocytes: Basophils, Eosinophils, Lymphocytes, Monocytes and Neutrophils) at Week 52

Maximum Observed Plasma Concentration (Cmax) of Tavaborole

Percentage of Participants With Complete Cure of Target Great Toenail (TGT) at Week 52

Time to Maximum Observed Plasma Concentration (Tmax) of Tavaborole

Change From Baseline in Chemistry Parameters (Alanine Aminotransferase, Alkaline Phosphatase and Aspartate Aminotransferase) at Week 24

Change From Baseline in Chemistry Parameters (Alanine Aminotransferase, Alkaline Phosphatase and Aspartate Aminotransferase) at Week 52

Change From Baseline in Chemistry Parameters (Albumin and Protein) at Week 24